Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × orantinib × Gastrointestinal × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 276 Oxaliplatin 235 Leucovorin 206 Capecitabine 176 Irinotecan 126 Gemcitabine 117 Cisplatin 112 Bevacizumab 103 Radiotherapy 70 Paclitaxel 58 Folfox protocol 54 Drug Therapy 45 Cetuximab 45 Sorafenib 42 S 1 (combination) 37 Docetaxel 37 Neoadjuvant Therapy 34 Chemotherapy, Adjuvant 34 pembrolizumab 31 XELOX 23 Surgical Procedures, Operative 23 lenvatinib 22 Radiation 22 Panitumumab 22 130-nm albumin-bound paclitaxel 20 Nivolumab 19 Chemoradiotherapy 19 regorafenib 18 atezolizumab 18 Doxorubicin 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01465464 2019-08-07

ORIENTAL

Taiho Pharmaceutical Co., Ltd.

Phase 3 Terminated

888 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡